$35M Series C Fuels Octave’s Commercial Momentum in Precision Neurology – Read the Release

Recent Announcements & Press

Octave® Bioscience, Inc. Announces Publication of Real-World Evidence Study in Multiple Sclerosis Journal – ET&C

Octave’s CEO Doug Biehn sits down with Nasdaq’s Leigh Hixon

Octave CEO Doug Biehn on NYSE Floor Talk with Judy Shaw

Octave Note

Leveraging Biology for Better Informed Treatment Decisions

Precision Medicine: Biomarkers as an Objective Measure

Octave at ECTRIMS: An Overview of Scientific Research Presented on Our MS Precision Care Solution

Media Library

living well

Being Diagnosed with Multiple Sclerosis

living well

Earliest Stages of Multiple Sclerosis

living well

Is My MS Controlled?